Literature DB >> 16177110

A dipalmitoylated lipoprotein from Mycoplasma pneumoniae activates NF-kappa B through TLR1, TLR2, and TLR6.

Takashi Shimizu1, Yutaka Kida, Koichi Kuwano.   

Abstract

The pathogenesis of Mycoplasma pneumoniae infection is considered to be in part attributed to excessive immune responses. Recently, lipoproteins from mycoplasmas have been reported to induce NF-kappaB activation. In this study, we examined the ability of lipoproteins from M. pneumoniae to activate NF-kappaB, and the active component responsible for the NF-kappaB activation was identified. Lipid-associated membrane proteins from M. pneumoniae were found to induce NF-kappaB through TLR 2 in a human monocytic cell line, THP-1. The active component of the Lipid-associated membrane proteins was a subunit b of F0F1-type ATPase (F0F1-ATPase). The F0F1-ATPase is assumed to contain two palmitic acids. The activation of NF-kappaB by the F0F1-ATPase was inhibited by a dominant negative construct of TLR1 and TLR6. These results indicate that the activation of NF-kappaB by F0F1-ATPase is dependent on TLR1, TLR2, and TLR6. The activity of the F0F1-ATPase was decreased with pretreatment of lipoprotein lipase but not protease, indicating that the lipid moiety of the F0F1-ATPase was important for the NF-kappaB activation. Thus, a dipalmitoylated lipoprotein from M. pneumoniae was found to activate NF-kappaB through TLR1, TLR2, and TLR6.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16177110     DOI: 10.4049/jimmunol.175.7.4641

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  58 in total

1.  Reactive oxygen species mediate Jak2/Stat3 activation and IL-8 expression in pulmonary epithelial cells stimulated with lipid-associated membrane proteins from Mycoplasma pneumoniae.

Authors:  Sang Yong Choi; Joo Weon Lim; Takashi Shimizu; Koichi Kuwano; Jung Mogg Kim; Hyeyoung Kim
Journal:  Inflamm Res       Date:  2012-01-24       Impact factor: 4.575

Review 2.  Interactions between mycoplasma lipid-associated membrane proteins and the host cells.

Authors:  Xiao-xing You; Yan-hua Zeng; Yi-mou Wu
Journal:  J Zhejiang Univ Sci B       Date:  2006-05       Impact factor: 3.066

3.  Synthesis and characterization of a dipalmitoylated lipopeptide derived from paralogous lipoproteins of Mycoplasma pneumoniae.

Authors:  Takeshi Into; Jun-ichi Dohkan; Megumi Inomata; Misako Nakashima; Ken-ichiro Shibata; Kenji Matsushita
Journal:  Infect Immun       Date:  2007-02-26       Impact factor: 3.441

Review 4.  Mycoplasma lipoproteins and Toll-like receptors.

Authors:  Ling-ling Zuo; Yi-mou Wu; Xiao-xing You
Journal:  J Zhejiang Univ Sci B       Date:  2009-01       Impact factor: 3.066

5.  Modulation of IL-8 boosted by Mycoplasma pneumoniae lysate in human airway epithelial cells.

Authors:  Kyung Eun Lee; Kyung Won Kim; Jung Yeon Hong; Kyu Earn Kim; Myung Hyun Sohn
Journal:  J Clin Immunol       Date:  2013-06-19       Impact factor: 8.317

Review 6.  Toll-like receptor signaling in primary immune deficiencies.

Authors:  Paul J Maglione; Noa Simchoni; Charlotte Cunningham-Rundles
Journal:  Ann N Y Acad Sci       Date:  2015-04-30       Impact factor: 5.691

Review 7.  New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections.

Authors:  Ken B Waites; Mitchell F Balish; T Prescott Atkinson
Journal:  Future Microbiol       Date:  2008-12       Impact factor: 3.165

8.  Hyperoside inhibits proinflammatory cytokines in human lung epithelial cells infected with Mycoplasma pneumoniae.

Authors:  Fang Liu; YuHua Zhao; JieMin Lu; ShuangHui Chen; XinGuang Zhang; WenWei Mao
Journal:  Mol Cell Biochem       Date:  2018-10-22       Impact factor: 3.396

Review 9.  Host defenses against bacterial lower respiratory tract infection.

Authors:  Taylor Eddens; Jay K Kolls
Journal:  Curr Opin Immunol       Date:  2012-07-25       Impact factor: 7.486

10.  Mycoplasma pneumoniae-derived lipopeptides induce acute inflammatory responses in the lungs of mice.

Authors:  Takashi Shimizu; Yutaka Kida; Koichi Kuwano
Journal:  Infect Immun       Date:  2007-10-22       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.